Markus A. Queisser

Markus A. Queisser

Auto-generated profile, based on publicly available information

Markus A. Queisser

GlaxoSmithKline Gunnels Wood Road Stevenage Hertfordshire SG1 2NY UK

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2021 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
MSMelanie Schneider
Melanie Schneider
CRChris J. Radoux
Chris J. Radoux
AHAndrew Hercules
Andrew Hercules
DODavid Ochoa
David Ochoa
IDIan Dunham
Ian Dunham
ALAndrew R. Leach
Andrew R. Leach

20 August 2021 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
RLRobert P. Law
Robert P. Law
JNJoao Nunes
Joao Nunes
CCChun‐Wa Chung
Chun‐Wa Chung
MBMarcus Bantscheff
Marcus Bantscheff
KBKarol Buda
Karol Buda
ABAndrew B. Benowitz
Andrew B. Benowitz

22 July 2020 in ACS Chemical Biology
Verified
Journal Article
Closed access
CCChun-Wa Chung
Chun-Wa Chung
HDHan Dai
Han Dai
EFEsther Fernandez
Esther Fernandez
CTChristopher P. Tinworth
Christopher P. Tinworth
ICIan Churcher
Ian Churcher
ABAndrew B. Benowitz
Andrew B. Benowitz

1 October 2017 in Journal of Cell Science
Verified
Journal Article
Open access
PDF file
JSJasmin Schulz
Jasmin Schulz
DADönem Avci
Dönem Avci
MQMarkus A. Queisser
Markus A. Queisser
AGAljona Gutschmidt
Aljona Gutschmidt
LDLena-Sophie Dreher
Lena-Sophie Dreher
JCJohn C. Christianson
John C. Christianson
The mammalian ubiquitin ligase Hrd1 is the central component of a complex facilitating degradation of misfolded proteins during the ubiquitin–proteasome-dependent process of ER-associated degradation (ERAD). Hrd1 associates with cofactors to execute ERAD, but their roles and how they assemble with Hrd1 are not well understood. Here, we identify crucial cofactor interaction domains within Hrd1 and report a previously unrecognised evolutionarily conserved segment within the intrinsically disordered cytoplasmic domain of Hrd1 (termed the HAF-H domain), which engages complementary segments in the cofactors FAM8A1 and Herp (also known as HERPUD1). This domain is required by Hrd1 to interact with both FAM8A1 and Herp, as well as to assemble higher-order Hrd1 complexes. FAM8A1 enhances binding of Herp to Hrd1, an interaction that is required for ERAD. Our findings support a model of Hrd1 complex formation, where the Hrd1 cytoplasmic domain and FAM8A1 have a central role in the assembly and activity of this ERAD machinery.

1 September 2020 in Cell Chemical Biology
Verified
Journal Article
Open access
SRSascha Röth
Sascha Röth
TMThomas J. Macartney
Thomas J. Macartney
AKAgnieszka Konopacka
Agnieszka Konopacka
KCKwok-Ho Chan
Kwok-Ho Chan
HZHoujiang Zhou
Houjiang Zhou
GSGopal Sapkota
Gopal Sapkota
K-RAS is known as the most frequently mutated oncogene. However, the development of conventional K-RAS inhibitors has been extremely challenging, with a mutation-specific inhibitor reaching clinical trials only recently. Targeted proteolysis has emerged as a new modality in drug discovery to tackle undruggable targets. Our laboratory has developed a system for targeted proteolysis using peptidic high-affinity binders, called "AdPROM." Here, we used CRISPR/Cas9 technology to knock in a GFP tag on the native K-RAS gene in A549 adenocarcinoma (A549GFPKRAS) cells and constructed AdPROMs containing high-affinity GFP or H/K-RAS binders. Expression of GFP-targeting AdPROM in A549GFPKRAS led to robust proteasomal degradation of endogenous GFP-K-RAS, while expression of anti-HRAS-targeting AdPROM in different cell lines resulted in the degradation of both GFP-tagged and untagged K-RAS, and untagged H-RAS. Our findings imply that endogenous RAS proteins can be targeted for proteolysis, supporting the idea of an alternative therapeutic approach to these undruggable targets.

2 November 2023 in Bioconjugate Chemistry
Verified
Journal Article
Open access
KCKarina Chan
Karina Chan
PSPreethi Soundarya Sathyamurthi
Preethi Soundarya Sathyamurthi
MQMarkus A. Queisser
Markus A. Queisser
MMMichael Mullin
Michael Mullin
HSHarry Shrives
Harry Shrives
GBGlenn A. Burley
Glenn A. Burley
Proteolysis targeting chimeras (PROTACs) are a family of heterobifunctional molecules that are now realizing their promise as a therapeutic strategy for targeted protein degradation. However, one limitation of existing designs is the lack of cell-selective targeting of the protein degrading payload. This manuscript reports a cell-targeted approach to degrade receptor-interacting serine/threonine-protein kinase 2 (RIPK2) in HER2+ cell lines. An antibody-PROTAC conjugate is prepared containing a protease-cleavable linkage between the antibody and the corresponding degrader. Potent RIPK2 degradation is observed in HER2+ cell lines, whereas an equivalent anti-IL4 antibody-PROTAC conjugate shows no degradation at therapeutically relevant concentrations. No RIPK2 degradation was observed in HER2- cell lines for both bioconjugates. This work demonstrates the potential for the cell-selective delivery of PROTAC scaffolds by engaging with signature extracellular proteins expressed on the surface of particular cell types.